ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $112.7 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 34.71% year-over-year to $112.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $539.0 million (down 13.01% YoY) and the FY2025 annual result came in at $128.3 million, down 32.87% from the prior year.
• Liabilities and Shareholders Equity declined to $112.7 million in Q1 2026 per PRQR's latest filing, from $128.3 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PRQR reached as high as $216.5 million in Q1 2022 and fell as low as $112.7 million in Q1 2026.
• A 5-year average of $160.0 million and a median of $156.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 99.79% — and 2025, when it grew 22.45%.
• Year by year, Liabilities and Shareholders Equity stood at $195.0 million in 2022, then retreated by 19.52% to $156.9 million in 2023, then gained by 21.81% to $191.1 million in 2024, then tumbled by 32.87% to $128.3 million in 2025, then dropped by 12.17% to $112.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $112.7 million, $128.3 million, and $141.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.